Effect of propolis among frailty comorbid COPD patients.

Effect of propolis among frailty comorbid COPD patients. - Effect of propolis among frailty comorbid COPD patients.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033212

Enrollment

Registered

2018-07-02

Start date

2018-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Propolis 101.7mg X3 per day, everyday, for 3 month. Placebo 101.7mg X3 per day, everyday, for 3 month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients with frailty or pre-frailty.

Exclusion criteria

Exclusion criteria: Patients with respiratory disease other than COPD.Patients with malignant tumor. Not able to assess the primary or secondary outcomes.

Design outcomes

Primary

Measure	Time frame
Difference of frailty index before and after intake of propolis.	—

Secondary

Measure	Time frame
Socres of QOL,CAT,HADS,mMRC, and spirometry	—

Countries

Japan

Contacts

Public ContactTetsuya Homma

Showa University School of Medicine Department of Medicine, Division of Allergology and Respiratory Medicine

oldham726@yahoo.co.jp03-3784-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026